168 related articles for article (PubMed ID: 21304035)
1. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data.
Mease PJ; Zimetbaum PJ; Duh MS; Vekeman F; Guérin A; Boerstoel-Streefland M; Jiang W; Lefebvre P
Ann Pharmacother; 2011 Feb; 45(2):179-88. PubMed ID: 21304035
[TBL] [Abstract][Full Text] [Related]
2. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
3. Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark.
Ishtiak-Ahmed K; Musliner KL; Christensen KS; Mortensen EL; Nierenberg AA; Gasse C
Am J Psychiatry; 2024 Jan; 181(1):47-56. PubMed ID: 37849303
[TBL] [Abstract][Full Text] [Related]
4. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Ishigooka J
Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
[TBL] [Abstract][Full Text] [Related]
5. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
[TBL] [Abstract][Full Text] [Related]
6. Antidepressants and the Risk of Cardiovascular Events in Elderly Affected by Cardiovascular Disease: A Real-Life Investigation From Italy.
Biffi A; Rea F; Scotti L; Lucenteforte E; Vannacci A; Lombardi N; Chinellato A; Onder G; Vitale C; Cascini S; Ingrasciotta Y; Roberto G; Mugelli A; Corrao G;
J Clin Psychopharmacol; 2020; 40(2):112-121. PubMed ID: 32134848
[TBL] [Abstract][Full Text] [Related]
7. Possible interaction between milnacipran and warfarin potassium.
Sawamura J; Kozaki K; Mochizuki S; Ishigooka J
J Clin Pharmacol; 2012 May; 52(5):780-1. PubMed ID: 22539653
[No Abstract] [Full Text] [Related]
8. Distinct effects of the serotonin-noradrenaline reuptake inhibitors milnacipran and venlafaxine on rat pineal monoamines.
Muneoka K; Kuwagata M; Ogawa T; Shioda S
Neuroreport; 2015 Jun; 26(9):510-4. PubMed ID: 26016648
[TBL] [Abstract][Full Text] [Related]
9. Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.
Perry NK
Postgrad Med J; 2000 Apr; 76(894):254-6. PubMed ID: 10727586
[TBL] [Abstract][Full Text] [Related]
10. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
11. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
[No Abstract] [Full Text] [Related]
12. Milnacipran for fibromyalgia.
Dempsey J
Issues Emerg Health Technol; 2008 Feb; (114):1-4. PubMed ID: 18354855
[TBL] [Abstract][Full Text] [Related]
13. Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.
Leo RJ; Brooks VL
Curr Opin Investig Drugs; 2006 Jul; 7(7):637-42. PubMed ID: 16869117
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of milnacipran: an overview.
Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():47-51. PubMed ID: 8923127
[TBL] [Abstract][Full Text] [Related]
15. Treatment with duloxetine in adults and the incidence of cardiovascular events.
Xue F; Strombom I; Turnbull B; Zhu S; Seeger J
J Clin Psychopharmacol; 2012 Feb; 32(1):23-30. PubMed ID: 22198454
[TBL] [Abstract][Full Text] [Related]
16. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
17. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.
Stahl SM; Grady MM; Moret C; Briley M
CNS Spectr; 2005 Sep; 10(9):732-47. PubMed ID: 16142213
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
Kasper S; Pletan Y; Solles A; Tournoux A
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants.
Montgomery SA
CNS Spectr; 2008 Jul; 13(7 Suppl 11):27-33. PubMed ID: 18622372
[TBL] [Abstract][Full Text] [Related]
20. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Saraceni MM; Venci JV; Gandhi MA
J Pharm Pract; 2014 Aug; 27(4):389-95. PubMed ID: 24381243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
